These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 21654389)

  • 1. Editorial: Double-edged swords: important factors connecting metabolic disorders and cancer development - from basic research to translational applications, volume II.
    Kung CP; Barnoud T; Yao CH; Bertolini I; Murphy ME
    Front Endocrinol (Lausanne); 2024; 15():1441828. PubMed ID: 38962679
    [No Abstract]   [Full Text] [Related]  

  • 2. [Management of mineral and bone disease caused by chronic renal disease: what recommendations have contributed].
    Houillier P;
    Nephrol Ther; 2008 Sep; 4 Spec No 1():2-8, 15-9. PubMed ID: 19031626
    [No Abstract]   [Full Text] [Related]  

  • 3. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.).
    Torregrosa JV; Bover J; Cannata Andía J; Lorenzo V; de Francisco AL; Martínez I; Rodríguez Portillo M; Arenas L; González Parra E; Caravaca F; Martín-Malo A; Fernández Giráldez E; Torres A;
    Nefrologia; 2011; 31 Suppl 1():3-32. PubMed ID: 21468161
    [No Abstract]   [Full Text] [Related]  

  • 4. The beehive and the merry-go-round in mineral metabolism.
    Wolf M; Bushinsky DA
    Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):329-30. PubMed ID: 21654389
    [No Abstract]   [Full Text] [Related]  

  • 5. [K/DOQI clinical practice guidelines for bone metabolism and disease in CKD].
    Sakaguchi T; Akizawa T
    Clin Calcium; 2004 Sep; 14(9):9-14. PubMed ID: 15577103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium metabolism in health and disease.
    Peacock M
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S23-30. PubMed ID: 20089499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D; Tatematsu M
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.
    Block GA
    Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):376-81. PubMed ID: 21519253
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.